Blog

Empowering small businesses to ditch the paperwork and fast-track new hire setup, Patriot’s employee self-onboarding feature lets new hires enter their own info securely-saving time, reducing errors, and giving employers one less stack of forms to deal with.

CANTON, OH / ACCESS Newswire / July 16, 2025 / Patriot Software, a leading provider of accounting and payroll software in the U.S., announces a new value-added feature for all payroll customers-employee self-onboarding for new hires. Employee self-onboarding significantly cuts down on administrative burdens and offers businesses a swift and professional method to integrate new hire information into their payroll system.

Many of Patriot’s existing customers have been adding new employees to their teams, prompting Patriot to prioritize this enhancement. The U.S. Bureau of Labor Statistics reported that small businesses added 5.4 million workers in March 2025 alone, underscoring the dynamic nature of the current job market. And in today’s competitive landscape, businesses that move quickly gain a significant advantage.

By automating onboarding tasks, Patriot helps businesses reduce manual data entry and avoid costly errors. With Patriot’s employee self-onboarding, new hires securely enter their essential personal details, bank, and tax information directly into the payroll software, all while keeping sensitive information protected and centralized.

“Employee self-onboarding does double duty-it saves time for employers and creates a seamless experience for employees,” said Amie Scarpitti, Product Manager at Patriot. “Employers should not have to spend their precious time sorting through stacks of paper forms, and new hires deserve a smooth experience. We’re proud to offer a modern onboarding experience that’s fast, secure, and eliminates unnecessary paperwork.”

Patriot is dedicated to helping American businesses operate more efficiently with powerful, easy-to-use accounting and payroll solutions. This commitment is clearly reflected in the latest feature. Based on feedback from early adopters, it’s hitting the mark. One customer noted, “It’s a great addition to Patriot Software,” while another shared, “I know it saved a lot of time on my end.”

Existing payroll customers can access the employee self-onboarding feature directly within their accounts when adding a new hire. Businesses interested in streamlining their accounting and payroll can learn more and schedule a demo at Patriot Software’s website. New customers receive a 30-day free trial and 50% off software pricing for the first three months.

—–

Patriot Software is disrupting the accounting and payroll industries with its low prices, achieving the 100th percentile for customer loyalty and satisfaction, and award-winning software. Patriot offers cloud-based accounting, payroll, HR, and time and attendance software solutions that help American businesses with up to 500 employees simplify their administrative tasks. Patriot’s US-based customer support team provides a personal touch that most software companies lack today. The company has been serving tens of thousands of businesses nationwide since 2002.

For more information, please contact:

Michele Bossart
Product Marketing Manager
mbossart@patriotsoftware.com
877-968-7147

SOURCE: Patriot Software, LLC

View the original press release on ACCESS Newswire

TAMPA, FL / ACCESS Newswire / July 16, 2025 / As temperatures rise across the Sunshine State, it might be tempting to stay inside and crank the air conditioning. But getting out into Florida’s wild spaces can help you stay cool while connecting with the beauty and power of nature!

Live Wildly, a nonprofit inspiring people to experience and protect Florida’s natural landscapes, is reminding Floridians that forests and freshwater springs offer their own natural air conditioning, with forests keeping temperatures as much as 13 degrees cooler than surrounding areas. And the state’s numerous natural springs provide refreshing escapes in clear waters that stay a cool 68-72 degrees year-round.

“Protecting Florida’s forests and other natural areas can help all of us stay cooler as temperatures rise,” said Lisa Shipley, CEO of the nonprofit Live Wildly. “Walking beneath shaded forest canopies, tubing down rivers, or taking a plunge into natural spring waters is a great way to beat the heat – and it’s a lot more fun than sitting inside staring at a screen!”

Whether you’re looking for a refreshing swim or a breezy trail to explore, here are Live Wild’s top five outdoor places to stay cool this summer:

1. Wekiwa Springs State Park: With crystal clear waters that stay a refreshing 72-degrees year-round, Wekiwa Springs is the perfect place to snorkel, swim, or just dangle your feet in crisp spring waters. Living up to its name – “wekiwa” comes from the Creek word meaning “bubbling water” – the park offers visitors natural swimming pools and the opportunity to float above a bubbling aquifer. Kayak rentals are available on-site to paddle the Wekiwa River. Located a quick 25-minute drive from Orlando, it’s the perfect place to explore nature while beating the heat. Reservations are required for entry, so make sure to plan ahead.

2. Devil’s Millhopper Geological State Park: Despite its devilish name, this Gainesville park provides visitors a lush and unexpected oasis. You’ll feel the temperature drop as you descend a staired-boardwalk into a 120-foot sinkhole. Small waterfalls and streams tumble down the steep limestone walls where thick vegetation thrives even in the driest of summers. Once at the bottom, enjoy the cool shade of a miniature rainforest. You might even spot shark teeth and other fossils embedded in the walls, revealing the ancient history of this geological wonder.

3. Delnor-Wiggins Pass State Park: This Gulf Coast beach, located along a barrier island near Naples, is considered one of the most pristine stretches of beach in the world. Enjoy cool ocean breezes while you swim, search for shells, or spot dolphins, manatees, and sea turtles swimming offshore. Bring your own kayak, canoe, or paddleboard to explore Water Turkey Bay. A hard-bottom reef located off the shoreline offers fun snorkeling and scuba diving opportunities.

4. Blackwater River State Park: Located in the panhandle, the park offers numerous ways to cool off along the meandering Blackwater River. You can fish along the river’s sandy banks or from the park’s numerous oxbow lakes. Rent kayaks, canoes, and tubes to float down the river’s shallow waters and pass over deep swimming holes. For those who prefer to stay dry, there are trails for hiking and biking in the shade of towering longleaf pines.

5. Guana Tolomato Matanzas National Estuarine Research Reserve: Enjoy the cool breezes and shady maritime forests of this sprawling research reserve while learning how estuaries benefit our daily lives (among other things, they filter our water, reduce flooding, and serve as nurseries for fish, crabs and shrimp). Visitors can paddle the serene waters of Guana Lake, the Guana River, and the Tolomato River, or hike trails while looking for some of the 200 bird species that have been recorded here. The reserve also offers guided tours during which you can learn about the human and natural history of this coastal habitat located just 20 minutes north of St. Augustine.

Live Wildly believes that the more people connect with nature, the more they’ll want to protect it. That’s why the organization is committed to preserving wild places, sharing their stories and empowering Floridians to be part of conservation solutions.

“These aren’t just beautiful places to visit,” said Shipley. “They’re vital ecosystems-and the heart of our State’s economic prosperity.

To find more cool outdoor escapes and learn how Live Wildly supports conservation efforts across Florida, visit LiveWildly.com and follow @LiveWildlyFL on social media.

About Live Wildly:
Live Wildly is a nonprofit organization dedicated to preserving Florida’s natural landscapes and wildlife. Through advocacy, education, and community engagement, Live Wildly works to raise awareness about the importance of conservation and empower individuals to take action to protect the environment. The organization is committed to safeguarding Florida’s rich biodiversity and ensuring a sustainable future for generations to come.

SOURCE: Live Wildly Foundation

Related Images

View the original press release on ACCESS Newswire

Company Doubles Missouri R&D Facility, Launches Heat Pump Testing, and Readies Fall Rollout of SOLIS™ & COR™ Mobile Nano-Grid System

WEST SENECA, NY / ACCESS Newswire / July 16, 2025 / Worksport Ltd. (NASDAQ:WKSP) (“Worksport” or the “Company”), a U.S. based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, today announced major corporate developments across research, manufacturing, and commercialization-signaling aggressive growth following a record-setting Q2.

Expanding U.S. R&D and Preparing for Manufacturing Scalability

After delivering Q2 2025 top-line results of $4.1M, up 83% from the previous quarter, Worksport shares that it has recently moved into new research and development (“R&D”) facilities in Ozark, Missouri, doubling its R&D footprint to facilitate larger R&D initiatives, paired with a large pipeline of upcoming and planned launches of innovative products and features. This expansion underscores the Company’s commitment to product innovation and expanding its customer reach through future-facing technology platforms. Missouri was selected due to its central geography, skilled labor force, and growing prominence as a U.S. manufacturing hub.

With production up over 50% since March 2025, the Company is also evaluating new factory capacity to meet surging demand. A decision on expansion is expected by the end of Q3. The Company shares that demand remains ahead of output.

COR and SOLIS Moving Toward Commercial Launch

Worksport’s highly anticipated SOLIS solar-integrated tonneau cover and COR portable nano-grid system remain on track for a Fall 2025 launch. Both products have completed major validation milestones, including third-party testing and customer-paid beta deployments. Management believes this clean-tech vertical-targeting a $13B addressable market-represents a transformational revenue stream and an expansion beyond the Company’s core truck accessory business.

The Company projects $2-3 million in revenue from SOLIS and COR in 2025, with 2026 expected to see 8-figure growth potential as sales expand across both business to consumer (B2C) and strategic enterprise channels.

AetherLux™ Gains Additional Enterprise Attention

Terravis Energy, Worksport’s clean-tech subsidiary, has entered early-stage commercial testing of its AetherLux™ Pro heat pump with high-performance Zerofrost technology, addressing the $148B global heat pump market. The technology is drawing interest from multi-billion-dollar corporations and U.S. government entities, with site visits and due diligence already underway.

Management believes AetherLux could play a major role in Worksport’s 2026 balance sheet, as the Company continues to validate its performance in extreme climate conditions and scale its manufacturing pathways.

For further information:

Investor Relations, Worksport Ltd. T: 1 (888) 554-8789 -128
W: investors.worksport.com W: www.worksport.com E: investors@worksport.com

Connect with Worksport Chief Executive Officer, Steven Rossi

Steven Rossi X (Twitter)

Steven Rossi LinkedIn

Join: Worksport’s Newsletter

About Worksport

Worksport Ltd. (Nasdaq:WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport’s hard-folding cover, designed and manufactured in-house, is compatible with all major truck models and is gaining traction with newer truck makers including the electric vehicle (EV) sector. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and Cold-Climate Heat Pump (CCHP) technology. Terravis Energy’s website is terravisenergy.com.

Connect with Worksport

Please follow the Company’s social media accounts on X (previously Twitter), Facebook, LinkedIn, YouTube, and Instagram (collectively, the “Accounts”), the links of which are links to external third-party websites, as well as sign up for the Company’s newsletters at investors.worksport.com.

Social Media Disclaimer

The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company. Investors and others should note that the Company announces material financial information to our investors using our investor relations website, press releases, Securities and Exchange Commission (SEC”) filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media. The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “scheduled,” “expect,” “future,” “intend,” “plan,” “project,” “envisioned,” “should,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial situation may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; and (iv) competition from other producers of similar products. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, including, without limitation, our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

SOURCE: Worksport Ltd.

View the original press release on ACCESS Newswire

FeelgoodzHospitality.com offers premium footwear designed to delight guests, ease operations, and advance sustainability goals.

GARNER, NC / ACCESS Newswire / July 16, 2025 / Feelgoodz, a leader in sustainable footwear, proudly announces the launch of www.FeelgoodzHospitality.com – a dedicated platform created to help resorts, boutique hotels, spas, and wellness clubs source premium, eco-conscious guest footwear while advancing sustainability goals across the hospitality industry.

The new site showcases Feelgoodz’s full luxury hospitality collection, including in-room slippers and spa slides, as well as retail items like natural rubber flip-flops and monogrammed Turkish towels. All products are crafted from natural, recycled, or regenerative materials and are designed to elevate the guest experience – while offering a meaningful memento of their stay. Each collection reflects Feelgoodz’s commitment to sustainable hospitality: offering exceptional guest footwear, supporting artisan communities, and reducing waste, particularly the growing issue of disposable slippers, which contribute significantly to landfills.

“We’re pioneering a new standard for hospitality footwear,” said Kyle Berner, founder of Feelgoodz. “Our collections deliver premium guest amenities and help lead the industry toward more thoughtful, sustainable alternatives.”

Key highlights of www.feelgoodzhospitality.com include:

• An expanded product collection featuring signature eco-luxe styles made from natural materials, recycled tires and grocery bags, upcycled textiles, and cruelty-free sherpa

• Custom branding options on all products

• Resources pertaining to waste reduction, streamlining operations, and supporting sustainability initiatives

• Insights into Feelgoodz’s artisan partnerships and materials sourcing

To explore the collection, request a sample, or learn more, visit www.FeelgoodzHospitality.com.

About Feelgoodz

Feelgoodz is a leader in sustainable, artisan-crafted footwear and accessories. With an unwavering commitment to transparency, accountability, and ethical production, Feelgoodz supports rural artisan partners across Thailand, Vietnam, India, Nepal, and Turkey. Feelgoodz remains steadfast in its mission to offer eco-friendly alternatives that enrich lives and preserve the planet. Discover more at www.feelgoodz.com & www.feelgoodzhospitality.com.

Contact Information

Kate Vessey
Director of Marketing
kate@feelgoodz.com

SOURCE: Feelgoodz

View the original press release on ACCESS Newswire

Capitalize Albany’s New RFP Advances Long-Awaited Development at Liberty Park

ALBANY, NY / ACCESS Newswire / July 16, 2025 / Capitalize Albany Corporation has issued a Request for Proposals (RFP) inviting qualified real estate developers to acquire and revitalize Liberty Park, a prominent 8-acre site in the heart of downtown Albany. This unique site, long regarded as one of the Capital Region’s most significant redevelopment opportunities, is now fully assembled, owned by Capitalize Albany and primed for transformative investment.

Liberty Park’s redevelopment comes at a critical time, coinciding with record momentum in downtown Albany. Over the past decade, the implementation of Capitalize Albany’s Impact Downtown Albany strategic plan has catalyzed over $385 million in new investment, resulting in the creation of more than 1,000 new multifamily residential units and major public infrastructure projects such as the Albany Skyway and Clinton Market Collective.

This opportunity is further bolstered by Governor Kathy Hochul’s more than $400 million Downtown Albany Championing Albany’s Potential (CAP) Initiative, which includes $200 million in targeted investment within a one-mile radius of the Capitol. Liberty Park is uniquely positioned to align with and benefit from this unprecedented state-level investment, located steps from some of the biggest attractions in the city including the New York State Capitol, Empire State Plaza, The Egg performance venue, New York State Museum and MVP Arena. This historic downtown location offers great access to all parts of New York’s capital city and is only minutes from major R&D assets, in an area with a regional population of more than 1.1 million and a labor force of more than 550,000.

“The release of this RFP marks a milestone moment for Liberty Park and for downtown Albany,” said Capitalize Albany Corporation president Ashley Mohl. “We’re aiming to generate strong interest and receive proposals that will unlock the full potential of this site. Marketing the site, identifying development opportunities, and evaluating proposals are the next major steps toward realizing this vision.”

The RFP is being actively marketed in partnership with CBRE Upstate-NY, which is leveraging its national and global reach to attract potential development partners. Proposals are due by 3:00 p.m. ET on August 26, 2025, and full RFP materials, including drone footage and site information, are available at www.libertyparkredevelopment.com.

Backed by robust public-sector collaboration, the Liberty Park development opportunity builds on more than seven years of strategic site assemblage led by Capitalize Albany. Key partners include Empire State Development, the Albany Convention Center Authority, the City of Albany Industrial Development Agency and Capitalize Albany’s Board of Directors.

The Liberty Park site encompasses approximately 8 acres, generally bounded by Broadway to the east, Hudson Avenue to the north, Liberty and Pruyn Streets to the south, and Green Street to the west. It contains 54 parcels which include four key structures, among them the former Trailways bus station and the Greyhound Bus Terminal, which was acquired by Capitalize Albany in October 2024. Discussions are ongoing to support the relocation of regional transit operations.

SOURCE: Capitalize Albany Corporation

View the original press release on ACCESS Newswire

Continuing to deliver vital support to the British Army 

SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 16, 2025 / Cubic Defence UK announces it has been awarded a two-year, sole-source contract by the UK Ministry of Defence (UK MOD) for the delivery of the Instrumented Live Training – Area Weapons Effects System (ILT-A).

“Cubic is honored to continue our long-standing partnership with the UK MOD,” said Alicia Combs, Vice President and General Manager at Cubic Defense. “This award reflects the trust placed in our systems to prepare warfighters for the complexities of modern combat. With ILT-A, we are proud to deliver a high-fidelity, globally interoperable solution that supports the British Army’s evolving training needs.”

ILT-A provides our soldiers with a realistic, data-rich training environment that enhances both competence and lethality,” said Simon Pearce, Synthetic Environments & Training, Defence Equipment and Support, UK Ministry of Defence. “The integration of Cubic’s Instrumented Metricized Live Fire capability and RPAS reflects the evolving character of combat and ensures the British Army can train with agility and precision.”

The ILT-A contract builds on Cubic’s two-decade legacy of integrated training solutions for the UK MOD and supersedes the previous Area Weapons Effects Simulation (AWES) contract. The system combines advanced laser and area-effects technology with fully instrumented live-fire range systems and Remotely Piloted Air Systems (RPAS), creating a digitized environment featuring multi-spectrum, multi-domain threats. It also integrates with Cubic’s SCOPIC2 Virtual-in-Live synthetic environment to enable comprehensive force training and supports interoperability with partner nations. Data generated during training is used to inform the After Action Review process.

The contract includes options to support the UK MOD and global allies with individual and collective training across multiple domains and training areas, from Section to Brigade level. It also features a life-extension program through the end of the decade and investment in experimentation to support UK MOD’s Force Development initiatives.

To learn more about Cubic products and services, visit www.cubic.com.

About Cubic
Cubic creates and delivers technology solutions in transportation that make people’s lives easier by simplifying their daily journeys, and defense capabilities that help promote mission success and safety for those who serve their nation. Led by our talented teams around the world, Cubic is driven to solve global challenges through innovation and service to our customers and partners.

Part of Cubic’s portfolio of businesses, Cubic Defense provides networked Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance (C5ISR) solutions and is a leading provider of live, virtual, constructive and game-based training solutions for both U.S. and Allied Forces. These mission-inspired capabilities enable assured multi-domain access; converged digital intelligence; and superior readiness for defense, intelligence, security and commercial missions. For more information, visit www.cubic.com.

Media Contact:

Geri MacDonald 
Cubic Defense 
geri.macdonald@cubic.com 

Touchdown PR for Cubic Defense

Cubicdefense@touchdownpr.com

SOURCE: Cubic Defense

View the original press release on ACCESS Newswire

DURHAM, NC / ACCESS Newswire / July 16, 2025 / On Glioblastoma Awareness Day, the Glioblastoma Foundation proudly announces the official launch of Gliolab, a CLIA-certified genomic testing laboratory dedicated exclusively to glioblastoma. Gliolab will offer three state-of-the-art genomic tests that together provide a personalized treatment roadmap for every patient diagnosed with this aggressive brain cancer, transforming care and access for thousands of families.

In a healthcare environment where 77% of cancer genomic testing claims were denied by private insurers in 2024, the Foundation has made a bold and unprecedented commitment: every glioblastoma patient will have access to this essential testing, regardless of their insurance status.

“This is a historic moment for the glioblastoma community,” said Dr. Gita Kwatra, PharmD, MBA, Co-founder and CEO of the Glioblastoma Foundation. “By launching Gliolab, we are changing the standard of care. Every glioblastoma patient deserves a treatment plan grounded in their tumor’s biology, not guesswork. Our genomic tests make that possible.”

The three tests now available through Gliolab include:

• Whole Genome DNA Methylation Profiling with Epignostix Classifier:
  This test uses DNA methylation patterns to precisely classify the tumor and identify copy number alterations, enabling more accurate diagnosis and prognosis.

• Comprehensive Genomic Profiling using PGDx Elio™ Tissue Complete:
  A broad next-generation sequencing (NGS) test that analyzes over 500 cancer-related genes to detect mutations, copy number changes, microsatellite instability (MSI), and tumor mutational burden (TMB).

• Gene Fusion Testing using Archer FusionPlex™ Pan Solid Tumor v2 Panel:
  This RNA-based test detects gene fusions and splicing variants that may be actionable or diagnostic in glioblastoma and other brain cancers.

Together, these three tests provide clinicians and patients with a personalized treatment roadmap to guide therapeutic decisions, enrollment in clinical trials, and identification of novel treatment options.

“As a neuro-oncologist who has treated glioblastoma patients for decades, I can say without hesitation: this kind of molecular insight is long overdue,” said Dr. Mark Gilbert, former Chief of the Neuro-Oncology Branch at the National Cancer Institute and advisor to the Glioblastoma Foundation. “The Foundation has done something extraordinary. Launching Gliolab and removing financial barriers to testing ensures that every patient-insured or not-gets the chance to receive optimal care.”

Under the Foundation’s innovative three-tiered payment plan:

• Patients with no insurance will receive free testing funded by philanthropy;

• Patients with Medicare and private insurance will only be responsible for a co-pay.

• The Foundation will be responsible for all other costs and claims.

This model ensures equity of access while emphasizing that personalized treatment is not a luxury-it should be the standard of care.

Physicians, hospitals, patients, and families seeking more information should contact the Foundation directly at info@glioblastomafoundation.org.

About the Glioblastoma Foundation

The Glioblastoma Foundation is a national nonprofit organization committed to transforming care for glioblastoma patients. Through genomic testing, translational research, drug development, and patient advocacy, the Glioblastoma Foundation works to improve outcomes and accelerate the path to a cure. To learn more please visit www.glioblastomafoundation.org.

Contact Information:

Ashley Pattman
Media Outreach Coordinator
info@glioblastomafoundation.org
919-402-1775

SOURCE: Glioblastoma Foundation

View the original press release on ACCESS Newswire

With over 4 million annual U.S. real estate transactions, a career in home inspection offers steady demand and is a natural fit for military who put prioritize safety and service

DENVER, CO / ACCESS Newswire / July 16, 2025 / Military members and their families seeking a new career path should look no further than home inspection. With unlimited earning potential and the flexibility to balance work with life, a career as a home inspector can open up the freedom to shape new careers and achieve success quickly–all with quality education and expert-led support through American Home Inspectors Training (AHIT) by The CE Shop.

AHIT is proud to support military transitions with a program designed to ensure success. Students are set up for success with unlimited access to Exam Prep Edge, an online study program specifically designed to help students pass their licensing exams on the first try. As an approved vendor for Army COOL, AHIT also honors our military by encouraging members to pursue credential assistance funds for new inspector training.

How to Get Started

Soldiers can use the Army IgnitED site to search for credentials they wish to pursue, like Home Inspection with AHIT. Before completing the CA (Credentialing Assistance) request for funds, it’s best to first talk with a military counselor to determine eligibility for Army Credentialing Assistance (Army CA) Program funding.If eligible, Army CA pays for things like training, exam fees, and other expenses related to the attainment or recertification of credentials up to an annual ceiling of $2,000.

Home inspection is a natural fit for those who put safety first, communicate effectively, enjoy solving problems, and take pride in hands-on work. With home inspection, military members can find a natural transition point by channeling their passion for service into another career that really makes a difference.

With more than 76,000 Home Inspectors trained since 1993, AHIT’s industry expertise is highly respected as one of the first trusted programs in the U.S. Geared toward success beyond required training, AHIT’s program is built to guide home inspectors through lucrative careers as industry-leading inspectors with agent preferred report writing techniques.

Here are some of the exclusive perks for those that qualify for Army COOL funding for AHIT education:

• An industry-leading learning platform that accelerates the learning experience.

• The flexibility of self-paced courses that work around individual schedules.

• Unlimited lifetime instructor support for guidance and advice.

• Live training led by experienced and successful inspectors.

• Engaging video content and interactive coaching that apply to real-life scenarios.

Check out a video overview here.

The Department of Defense and the Department of the Army are neither affiliated with nor endorse American Home Inspectors Training.

About AHIT, by The CE Shop

AHIT by The CE Shop is the leading provider of home inspection training, certifications, continuing education, and professional development courses. Between live classroom training and online course options, we offer the flexibility to fit anyone’s schedule. Whether you’re a seasoned pro or launching a new career, The CE Shop offers online professional education across real estate, mortgage, home inspection, and appraisal throughout the United States. We believe that the right education can truly make a difference. Visit AHIT.com and TheCEShop.com to learn more.

Media Contact:
Liz Meitus
Liz.Meitus@TheCEShop.com
720-822-5314

SOURCE: The CE Shop LLC

View the original press release on ACCESS Newswire

Commercial roadmap includes: first joint bGen TES projected expected to launch in 2027, three projects worth $50 million by 2030, and develop a pipeline of 15-20 projects with a potential value of $650 million by 2035

Pilot integrations planned to power AI data centers

SMR capacity could reach up to 120 GW by 2050, requiring more than $670 billion in global investment according to theInternational Energy Agency (IEA)

ROSH HA‘AYIN, IL / ACCESS Newswire / July 16, 2025 / Brenmiller Energy Ltd. (Nasdaq:BNRG), (the “Company”, “Brenmiller” or “Brenmiller Energy”) a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, announced today it has signed of a non-binding Memorandum of Understanding (“MoU”) with ENASCO Ltd. (“ENASCO”), a specialist in nuclear Small Modular Reactor (“SMR”) project development. The collaboration marks another step towards Brenmiller’s expansion into the nuclear energy sector and aligns with the Company’s recent announcement that it is developing a new version of its TES to be tailored for SMR and high-resilience industrial applications.

Under the MoU, Brenmiller and ENASCO will collaborate to study, develop and commercialize integrated solutions combining Brenmiller’s proprietary bGen™ TES system with advanced Liquid Metal Reactor (“LMR”)-based SMRs. The initiative targets enhanced energy efficiency, operational safety, and system flexibility across electric, thermal, and hydrogen applications.

“In cooperation together with ENASCO, we plan to leverage our complementary capabilities to explore creating a scalable, high-efficiency hybrid platform that answers the energy market’s need for clean and dispatchable baseload power,” said Doron Brenmiller, Chief Business Officer of Brenmiller Energy. “In the near term, we plan to target the AI data center market which, according to a McKinsey & Co. report, will account for almost 12% of total power demand in the U.S. by 2030.”

Commercial Roadmap and Market Potential

According to the International Energy Agency (IEA), SMR capacity could reach up to 120 GW by 2050, requiring more than $670 billion in global investment. The MoU outlines a phased roadmap, including:

• 2026: Form strategic alliances with SMR vendors and pilot integration with AI data centers

• 2027: Launch first joint hybrid SMR+TES project

• 2030: Deploy three commercial-scale projects with a combined target value of $50 million

• By 2035: Build a pipeline of 15-20 hybrid projects across Europe and the Americas, with a potential value of up to $650 million

Strategic Rationale: Enabling the Future of Nuclear-Thermal Hybrid Systems

The bGen™ TES system is uniquely positioned to address core challenges in SMR deployment. When coupled with LMRs-known for their high operating temperatures (~500-550°C) and low-pressure designs-bGen™ offers:

• Enhanced Passive Safety: Acts as a passive heat sink during emergency shutdowns or grid outages, improving SMR safety

• Streamlined Design: Eliminates the need for separate steam generators or redundant heat exchangers, reducing CapEx

• Grid Flexibility: Supports load following, time-shifting, and ancillary market participation

• Scalability: Supports a wide range of project sizes, from 10 MWh pilots to multi-GWh utility-scale systems

About ENASCO Ltd.

ENASCO Ltd. provides advanced engineering, feasibility analysis, and strategic consulting for SMR deployments across Europe. With an established track record in nuclear energy design, grant writing, consortium management, and policy advisory, ENASCO is a recognized contributor to the evolution of modular nuclear infrastructure.

About bGen™

bGen™ ZERO is Brenmiller’s TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME’s Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards.

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when discussing: the terms of the MoU with ENASCO Ltd. and potential projects and pipeline as a result of the MoU; that the Company together with ENASCO plans to leverage complementary capabilities to explore creating a scalable, high-efficiency hybrid platform that answers the energy market’s need for clean and dispatchable baseload power; that the Company plans to target the AI data center market which will account for almost 12% of total power demand in the U.S. by 2030; that SMR capacity could reach up to 120 GW by 2050 and require more than $670 billion in global investment; that the bGen TES system is uniquely positioned to address core challenges in SMR deployment; and the benefits of bGen when coupled with LMRs . The Company and ENASCO Ltd. may not ultimately reach agreement on definitive agreements and the transactions and projects contemplated by the MoU may not occur. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, comments on the extension of the MPox Public Health Emergency of International Concern (PHEIC) by WHO.

The Director General of WHO has extended the PHEIC declaration for MPox epidemic according to a WHO news release dated July 10, 2025, following continuing upsurge of the MPox virus (MPXV) epidemics in the African region^[1].

Sporadic travel related cases of MPXV Clade I have occurred outside Africa, including in the USA, but so far have not resulted in further transmission. The threat of such sustained transmission continues, and is part of the decision to continue the PHEIC status.

“Our development of NV-387 towards Phase II clinical trial for treatment of MPOX is timely for responding to the continuing threat of a global spread of MPox, and for meeting the need for treatment of MPox patients in Africa, in light of the continuing spread of MPox,” said Anil R. Diwan, PhD, President and Executive Chairman of NanoViricides, Inc., adding, “If successful, this NV-387 clinical trial will also open up a multi-billion-dollar global market of preparedness for poxvirus bioterrorism to us.”

At present, there is no drug approved, that is actually safe and effective in humans, for the treatment of the MPox disease, which is caused by MPXV infection. Tecovirimat (SIGA) has failed to show any effectiveness over standard of care in a clinical trial for treatment of MPXV infections. Brincidofovir treatment resulted in drug-induced liver disease in three out of three treated MPox patients resulting in cessation of therapy, and did not show any effectiveness in these patients according to a peer reviewed “retrospective observational study” also called “non-randomized study”^[2], ^[3]. In spite of this, a clinical trial of brincidofovir for treating MPox was initiated under an international coalition led by US CDC and first patient was dosed around January 2025 in this “MOSA” clinical trial^[4]. The topline results from this clinical trial regarding safety and efficacy were anticipated by CY Q2 (i.e. June, 2025). We have not found any press releases announcing any such results.

The orthopoxviruses can escape both small chemical drugs, tecovirimat and brincidofovir, by mutations, according to peer reviewed scientific articles^[5].

The above factors clearly highlight the need for an effective therapeutic for the treatment of MPOX.

In contrast to the small chemical drugs, vaccines, antibodies, that viruses escape readily, NV-387, the novel broad-spectrum antiviral developed by the Company, is designed such that viruses would not escape the drug. This is because NV-387 mimics the cell-side feature called heparan sulfate proteoglycans (HSPG) to which the viruses bind and concentrate next to the cell before they can attack the cell and cause infection. No matter how much a human pathogenic virus mutates, it continues to bind to HSPG. Over 90% of human pathogenic viruses are known to bind to HSPG.

Additionally, NV-387 has been found to be extremely safe and well tolerated in a Phase I human clinical trial. There were no reported adverse events or serious adverse events in this clinical trial. In animal studies, NV-387 was found to be extremely safe, with a No-Observed-Adverse-Event Level (NOAEL) of the drug at 1,200 mg/kg, and the Maximum Tolerated Dose (MTD) at 1,500 mg/kg in intravenous injection in rats. The Phase I clinical trial results for NV-387 were consistent with the safety observations in animal model studies.

NV-387 is orally available and is formulated as oral gummies that are soft solids that do not require swallowing, and are designed to dissolve in the oral cavity itself. This is important because MPox patients may not have the ability to swallow pills or capsules because of viral lesions in the oral cavity.

The Company recently announced that it has completed the development of a clinical trial protocol for the impending Phase II study of NV-387 for the treatment of MPox disease in the African Region. This will be a randomized clinical trial comparing NV-387 treatment with the Standard of Care, to evaluate the dosing regimen for NV-387, the safety and tolerability of the dosing regimen in MPox patients, and effectiveness of NV-387 on the MPXV virus and the MPox disease that it causes.

Of note, both tecovirimat and brincidofovir were approved by the US FDA for smallpox virus, based on the “Animal Rule”, which avoids the use of human efficacy clinical trials that would be unethical to conduct with a smallpox challenge study in humans.

We also note that smallpox is a more severe disease than even the most severe form of MPox disease, and both of these drugs have been found to be inadequate for the treatment of MPox according to currently available datasets (although definitive data from the brincidofovir clinical trial has not been released yet).

These two drugs (tecovirimat and brincidofovir) have been acquired in the US Strategic National Stockpile for bioterrorism preparedness to the tune of around billion dollars. The overall global market for bioterrorism preparedness against smallpox variants is estimated to be several billions of dollars.

The Company anticipates that a successful Phase II clinical trial of NV-387 for the treatment of MPox would open up the US Government SNS market and similar global markets to our drug and benefit the Company’s other programs as well.

MPXV Clade Ib strain is dominant in major parts of Africa and continues to spread, whereas the less virulent MPXV Clade IIb strain is dominant in Sierra Leone, with cases increasing at present. While vaccination has started, overall, the uptake of available vaccines has remained lower than anticipated due to logistical, operational, and financial barriers, according to the report of the International Health Regulations (2005) (IHR) Emergency Committee for MPox of the WHO on June 5, 2025.

MPXV Clade II has become epidemic, within limited population demographics, in the Western world including the USA since a 2022 epidemic it caused, driven by travel-related transfer from Western Africa.

The PHEIC regarding MPox 2024 was first declared on August 14, 2024, and was extended in February 2025. It has been extended again now as the MPXV continues to spread in neighboring countries in Africa threatening further global spread and sustained transmission.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire